P h a r m a c e u t i c a l
-
Upload
ayswarya-anil -
Category
Business
-
view
351 -
download
0
Transcript of P h a r m a c e u t i c a l
![Page 1: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/1.jpg)
Pharmaceutical Industry
![Page 2: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/2.jpg)
![Page 3: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/3.jpg)
Indian pharmaceutical industry
• The Indian pharmaceutical industry is the world's second-largest by volume and is likely to lead the manufacturing sector of India.
• The first pharmaceutical company are Bengal Chemicals and Pharmaceutical Works, which still exists today as one of 5 government-owned drug manufacturers, appeared in Calcutta in 1930.
• The government started to encourage the growth of drug manufacturing by Indian companies in the early 1960s, and with the Patents Act in 1970
![Page 4: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/4.jpg)
![Page 5: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/5.jpg)
WORLD SCENARIO
• The global pharmaceutical market is estimated to represent a $48 billion opportunity for India by 2011, in terms of:
• manufacturing outsourcing-supply of active pharmaceutical ingredients (APIs) and intermediates
development outsourcing-conducting preclinical and clinical trials
customized chemistry services-contract research services for compounds pre-launch.
![Page 6: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/6.jpg)
INDIAN SCENARIO
India's pharmaceutical market grew at 15.7% during December 2011.globally, India ranks third in terms of manufacturing pharma products volume. The indian pharmaceutical industry is expected the grow at a rate of 9.9% till 2010 after that 9.5% till 2015
![Page 7: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/7.jpg)
![Page 8: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/8.jpg)
![Page 9: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/9.jpg)
![Page 10: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/10.jpg)
![Page 11: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/11.jpg)
![Page 12: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/12.jpg)
![Page 13: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/13.jpg)
![Page 14: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/14.jpg)
![Page 15: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/15.jpg)
![Page 16: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/16.jpg)
![Page 17: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/17.jpg)
![Page 18: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/18.jpg)
![Page 19: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/19.jpg)
![Page 20: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/20.jpg)
![Page 21: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/21.jpg)
![Page 22: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/22.jpg)
![Page 23: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/23.jpg)
Emerging Trends & Opportunities
• Geographic Convergence– Established and growing destination for Generic product
development and manufacturing– Leading Indian companies seeking overseas markets and
global scale
• Generic – Innovator Convergence– Leading Indian companies trying to climb the value chain
into innovative research– India developing into a Drug Discovery services outsourcing
destination
![Page 24: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/24.jpg)
![Page 25: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/25.jpg)
![Page 26: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/26.jpg)
Patents and generics
• A chemical patent or pharmaceutical patent is a patent for an invention in the chemical or pharmaceuticals industry
• Depending on a number of considerations, a company may apply for and be granted a patent for the drug
![Page 27: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/27.jpg)
CSR It is particularly difficult for pharmaceutical companies to allocate its strategic resources necessary to CSR strategies, due to so much of its funds are allocated for R&D and promotional activities, which are relatively risky in nature. The demand for its products is based on consumer motivation, which can vary greatly amongst different countries depending on the responsibilities of consumers, government and economies, and insurance companies or a mix of the three..
![Page 28: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/28.jpg)
28
Challenges & RecommendationsChallenges
Low Government funding & lack of efficient execution of schemes & initiatives
Shortfall in Health care infrastructure and Workforce
Inadequate accessibility to affordable quality services
Financial constraints with respect to infrastructural needs
Recommendations
Step-up in Government funding and initiatives via a special task force
Implementation of REITs and increased use of Private-Private Partnership Models
Addressing geographic accessibility through PPP and harnessing local resources
Creating a Global Source of Skill
Efficient dissemination of healthcare related information
Establishment of Industry Body with adequate representation from all stakeholders
![Page 29: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/29.jpg)
Key successful factors
• Supplier/Partner mapping/selection– Capability / Keenness / Reliability / Competitiveness– Key team members – development, regulatory & commercial
• Optimal Number of Partners– Strategic – markets/product lines– Opportunistic – product specific
• Relationship management– Relationship oriented culture
• Contract negotiation– Clear distribution of responsibilities and timelines– Demand performance - penalties for not meeting deliverables
• Project management– Regular visits and video/teleconferences a must
![Page 30: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/30.jpg)
RANBAXY SWOT ANALYSIS
STRENGTHS:
➢ Low cost of production. ➢ Large pool of installed capacities ➢ Efficient technologies for large
number of Generics.
![Page 31: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/31.jpg)
• Large pool of skilled technical manpower.• ➢ Increasing liberalization of government
policies
![Page 32: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/32.jpg)
• WEAKNESS:• ➢ Fragmentation of installed capacities.• ➢ Low technology level of Capital Goods of
this section.• ➢ Non-availability of major intermediaries for
bulk drugs.• ➢ Lack of experience to exploit efficiently the
new patent regime.
![Page 33: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/33.jpg)
• OPPORTUNITY:• ➢ Aging of the world population.• ➢ Growing incomes.• Growing attention for health.• ➢ New diagnoses and new social diseases.• ➢ Spreading prophylactic approaches.• ➢ Saturation point of market is far away
![Page 34: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/34.jpg)
• THREATS:• ➢ Containment of rising health-care cost.• High Cost of discovering new products and
fewer discoveries.• ➢ Stricter registration procedures.• ➢ High entry cost in newer markets.• ➢ High cost of sales and marketing.
![Page 35: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/35.jpg)
![Page 36: P h a r m a c e u t i c a l](https://reader033.fdocuments.us/reader033/viewer/2022052620/55786bc5d8b42a14628b4609/html5/thumbnails/36.jpg)